TP53 and osteosarcoma: To confirm the proposed interaction between loss of TP53 and the evolutionary pressures that are induced by platinum treatment, we studied the post-treatment bone marrow sample of another LFS patient (UPN034, n = 9 HSPC clones), who had been previously treated for osteosarcoma (DX1) with, among other treatments, cisplatin.